<DOC>
	<DOCNO>NCT01885078</DOCNO>
	<brief_summary>The purpose study investigate long-term safety side effect baricitinib participant complete previous baricitinib rheumatoid arthritis study . The study provide 5 year additional treatment baricitinib .</brief_summary>
	<brief_title>An Extension Study Participants With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Have complete final active treatment study JADV ( NCT01710358 ) , JADZ ( NCT01711359 ) , JADX ( NCT01721057 ) , JADW ( NCT01721044 ) , JADA ( NCT01185353 ) JAGS ( plan start date August 2014 ) Have significant uncontrolled cerebrocardiovascular ( eg , myocardial infarction [ MI ] , unstable angina , unstable arterial hypertension , severe heart failure , cerebrovascular accident ) , respiratory , hepatic , renal , gastrointestinal , endocrine , hematologic , neuropsychiatric disorder , abnormal laboratory value develop previous baricitinib study , opinion investigator , pose unacceptable risk participant investigational product continue administer Have know hypersensitivity baricitinib component investigational product Had investigational product permanently discontinue time previous baricitinib study Had temporary investigational product interruption final study visit previous baricitinib study , opinion investigator , pose unacceptable risk participation study Have condition , opinion investigator , render participant unable understand nature , scope , possible consequence study precludes participant follow completing protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>